Genetic Diseases: Screening, Management, and Societal Implications
With Sophie and Marcus, Biology & Physiology Specialist
Key Takeaways
- Three main categories: chromosomal conditions like Down's, Edwards' and Patau's syndromes; single-gene disorders like cystic fibrosis, sickle cell disease, and Huntington's; and multifactorial conditions influenced by both genes and environment, like neural tube defects.
- The combined first trimester screening — nuchal translucency ultrasound plus blood markers at 11 to 14 weeks — assesses the probability of trisomies 21, 18, and 13.
- Cell-free fetal DNA testing offers higher sensitivity for high-risk pregnancies.
- Screening tells you probability — a 1 in 50 chance of Down's syndrome, for example.
- Diagnosis confirms or excludes the condition.
Listen to This Episode
Full interactive lesson available inside the course — Start learning →
Full Transcript
Sophie: Our final episode today covers Genetic Diseases: Screening, Management, and Societal Implications. I'm Sophie, and with me is Marcus, our Biology and Physiology Specialist. Marcus, what types of genetic conditions are most relevant to midwifery practice?
Marcus: Three main categories: chromosomal conditions like Down's, Edwards' and Patau's syndromes; single-gene disorders like cystic fibrosis, sickle cell disease, and Huntington's; and multifactorial conditions influenced by both genes and environment, like neural tube defects.
Sophie: What prenatal screening options are available in the UK for chromosomal conditions?
Marcus: The combined first trimester screening — nuchal translucency ultrasound plus blood markers at 11 to 14 weeks — assesses the probability of trisomies 21, 18, and 13. Cell-free fetal DNA testing offers higher sensitivity for high-risk pregnancies.
Sophie: What's the distinction between screening and diagnostic testing?
How does genetic diseases: screening, management, and societal implications work in a healthcare context?
Marcus: Screening tells you probability — a 1 in 50 chance of Down's syndrome, for example. Diagnosis confirms or excludes the condition. Diagnostic options include amniocentesis and chorionic villus sampling, both of which carry a small risk of miscarriage.
Sophie: How do midwives support women through the decision to have screening?
Marcus: By ensuring truly informed consent — explaining what screening can and cannot tell you, what happens if the result is high-risk, and what the diagnostic options involve. The decision whether to screen at all is deeply personal and must be respected.
Sophie: What management options exist when a genetic condition is confirmed prenatally?
Marcus: Women may choose to continue the pregnancy with enhanced planning and specialist support, or they may consider termination. For conditions like spina bifida, fetal surgery is available in specialist centres. The midwife's role is to support, not to direct.
Why is genetic diseases: screening, management, and societal implications important in midwifery practice?
Sophie: How should midwives navigate the ethical tensions around genetic screening?
Marcus: By anchoring every interaction in the individual woman's values and circumstances, and by staying current with professional guidance from the NMC and RCOG. Ethics is not about having the right answer — it's about asking the right questions with care and humility.
Sophie: A really important note to end on. Thank you, Marcus.
Marcus: Thanks, Sophie. Genetics is one of the most rapidly evolving areas of medicine — staying curious and informed will be part of midwifery practice for your whole career.